Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 43 min ago
Peer-reviewedLicence not statedEuropean Annals of Otorhinolaryngology, Head and Neck Diseases

Treatment of epistaxis in Osler-Weber-Rendu disease by bevacizumab nasal spray. The EROSB study: Determining the effective dose

  • L. Vincent
  • L. Robard
  • C. Creveuil
  • E. Babin
  • Marion Perréard
  • M. Humbert
Open at sourceDOICite

Related

  1. Which treatment is most effective at reducing the damage caused by the pest box tree moth? A case in a Mediterranean mountain
    Fiona Corominas, Lluís Vilar, Jordi Bou
    PeerJPeer-reviewedCC BY 4.0Full textEcologyCrossrefEurope PMCDOAJ
  2. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
    Isabelle Ollivier-Hourmand, Manon Allaire, Jean Paul Cervoni +11
    Journal of HepatologyPeer-reviewedLicence not statedFull text17 citedGeneral biologyHAL
  3. Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
    Edoardo Cammarata, Chiara Airoldi, Jacopo Colombo +18
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textImmunologyEurope PMC
  4. Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease
    M. Dittmann, D. M. Johnson, M. Rapp +26
    bioRxivPreprintCC BY-NC-NDFull textImmunologybioRxiv
  5. Bimekizumab for Darier disease: A case report highlighting dual IL-17A and IL-17F inhibition as a potential treatment.
    Weipeng Xie, Priya Agarwal, Medha Rao +1
    JAAD case reportsPeer-reviewedCC BYFull textGenetics & genomicsEurope PMC

Cite

BibTeXRIS
BibTeX
@article{vincent2026treatment,
  title = {{Treatment of epistaxis in Osler-Weber-Rendu disease by bevacizumab nasal spray. The EROSB study: Determining the effective dose}},
  author = {L. Vincent and L. Robard and C. Creveuil and E. Babin and Marion Perréard and M. Humbert},
  journal = {European Annals of Otorhinolaryngology, Head and Neck Diseases},
  year = {2026},
  month = sep,
  doi = {10.1016/j.anorl.2024.10.006},
  url = {https://normandie-univ.hal.science/hal-05659269v1},
}
RIS
TY  - JOUR
TI  - Treatment of epistaxis in Osler-Weber-Rendu disease by bevacizumab nasal spray. The EROSB study: Determining the effective dose
AU  - L. Vincent
AU  - L. Robard
AU  - C. Creveuil
AU  - E. Babin
AU  - Marion Perréard
AU  - M. Humbert
PY  - 2026
DA  - 2026/09/21
JO  - European Annals of Otorhinolaryngology, Head and Neck Diseases
DO  - 10.1016/j.anorl.2024.10.006
UR  - https://normandie-univ.hal.science/hal-05659269v1
SN  - 1879-7296
SN  - 1879-730X
ER  -